targets for the central regulation of body weight. CNS Neurol Disord Drug Targets 2006; 5: 263-74. 71. Nargund RP, Strack AM, Fong TM. Melanocortin-4 receptor (MC4R) agonists for the treatment of obesity. J Med Chem 2006; 49: 4035-43. 72. van den Hoek AM, Heijboer AC, Corssmit EP, Voshol PJ, Romijn JA, Havekes LM, Pijl H. PYY3-36 Reinforces Insulin Action on Glucose Disposal in Mice Fed a HighF...

Aim of work: The role of pancreatic polypeptide family including Neuropeptide Y (NPY), and Peptide Tyrosine Tyrosine (PYY) in obesity development and its metabolic changes is controversial due to multiple receptor involvement. Therefore, this study was designed to investigate the effect of a potent Y2 receptor agonist; Peptide Tyrosine Tyrosine (PYY3-36) on high fat diet (HFD) induced obesity i...

RECENTLY, the United States Food and Drug Administration (FDA) decided for the present against approving the cannabinoid receptor antagonist Rimonabant for the treatment of obesity in the United States. This decision resulted mainly from concerns based on studies showing that the drug’s benefits would not outweigh its risks for side effects. This decision further diminished already limited hope...

Functional magnetic resonance imaging has become a powerful tool to investigate the neuroendocrinology of appetite. In a recent study, we demonstrated that the brain activation pattern seen following the infusion of the anorectic gut hormones PYY3-36 and GLP-17-36 amide to fasted individuals resembles the brain activation pattern seen in the physiological satiated state. This commentary discuss...